A Phase Ⅳ Clinical Trial to Evaluate the Safety and Immunogenicity of 23 Valent Pneumococcal Polysaccharide Vaccine Revaccinated in 60-70 Years Old in Shanghai
Latest Information Update: 21 Feb 2022
At a glance
- Drugs Pneumococcal vaccine (Primary)
- Indications Pneumococcal infections
- Focus Pharmacodynamics
- Sponsors China National Biotec Group
- 15 Feb 2022 Status changed from recruiting to completed.
- 14 Apr 2021 Status changed from not yet recruiting to recruiting.
- 14 Jan 2021 New trial record